Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

Fenebrutinib, an experimental oral BTK inhibitor, significantly reduced relapse rates and MRI markers of disease activity compared with Aubagio in two large Phase 3 trials for relapsing multiple ...

The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...

A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that ...

WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing ...

Disability accumulation may occur independently of relapses for some patients in the early phase of relapsing-remitting multiple sclerosis (MS), according to new research. Approximately 61% of ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

MS is due to the body’s defence system, or immune system, attacking the insulating cover of myelin that protects the nerves. This damages the nerves and impairs their ability to pass on electric ...